J. Bérille

发表

Predictive factors of positive circumferential resection margin after radiochemotherapy for rectal cancer: the French randomised trial ACCORD12/0405 PRODIGE 2.

T. Conroy, A. Leroux, I. Soubeyran, 2013, European journal of cancer.

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

J. Dancey, F. Shepherd, R. Ramlau, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis.

S. Michiels, F. André, P. Ganz, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Sequence-dependent cytotoxic effects of the combination of a new nitrosourea, fotemustine, with 5-fluorouracil plus folinic acid

G. Milano, J. Bérille, J. Fischel, 2004, Cancer Chemotherapy and Pharmacology.

Fotemustine in the treatment of brain primary tumors and metastases.

D. Khayat, J. Bérille, B. Gerard, 1994, Cancer investigation.

Phase II trial of docetaxel with dexamethasone premedication in patients with advanced non-small cell lung cancer: the Canadian experience

K. Gelmon, F. Shepherd, J. Bérille, 1998, Investigational New Drugs.

A multicenter, randomized phase III study of docetaxel + cisplatin (DC) vs docetaxel + carboplatin (DCb) vs vinorelbine + cisplatin (VC) in chemotherapy-naive patients (Pts) with advanced and metastatic non-small cell lung cancer (NSCLC)

F. Fossella, M. Millward, J. Bérille, 2000 .

Summary of phase II data of docetaxel (Taxotere), an active agent in the first- and second-line treatment of advanced non-small cell lung cancer.

F. Fossella, J. Bérille, J. Lee, 1995, Seminars in oncology.

A phase II trial of fotemustine and cisplatin in central nervous system metastases from non-small cell lung cancer.

B. Croisile, P. Souquet, J. Bérille, 1996, European journal of cancer.

Phase I-II and pharmacokinetic study of a new fotemustine schedule in advanced non-small cell lung cancer.

A. Le Cesne, T. le Chevalier, M. Marty, 1995, Lung cancer.

Docetaxel (Taxotere) plus cisplatin: an active and well-tolerated combination in patients with advanced non-small cell lung cancer.

N. Ibrahim, A. Monnier, J. Douillard, 1998, European journal of cancer.

Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis.

S. Michiels, F. André, P. Ganz, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer.

R. James, M. Friedlander, J. Zalcberg, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III randomized trial of definitive chemoradiotherapy (CRT) with FOLFOX or cisplatin and fluorouracil in esophageal cancer (EC): Final results of the PRODIGE 5/ACCORD 17 trial.

J. Douillard, V. Boige, O. Bouché, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sequential administration of docetaxel followed by cisplatin-vindesine: a pilot study in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).

D. Khayat, J. Spano, J. Bérille, 2005, Bulletin du cancer.

Pharmacokinetic evaluation of the vinorelbine–lapatinib combination in the treatment of breast cancer patients

J. Bonneterre, S. Urien, V. Diéras, 2011, Cancer Chemotherapy and Pharmacology.

Overview of docetaxel (Taxotere)/cisplatin combination in non-small cell lung cancer.

R. James, J. Zalcberg, M. Millward, 1999, Seminars in oncology.

Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.

T. Conroy, M. Ychou, C. Bascoul-Mollevi, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survival

J. Pignon, M. Ychou, M. Ducreux, 2011, Radiation oncology.

Results of the GYNECO 02 study, an FNCLCC phase III trial comparing hysterectomy with no hysterectomy in patients with a (clinical and radiological) complete response after chemoradiation therapy for stage IB2 or II cervical cancer.

C. Haie-meder, P. Rouanet, D. Cowen, 2012, The oncologist.

Alpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel.

J. Rigas, J. Bérille, R. Bruno, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC).

K. Roszkowski, M. Krzakowski, A. Parisi, 2000, Lung cancer.

Cisplatin-fotemustine combination in inoperable non-small cell lung cancer: preliminary report of a French multicentre phase II trial.

A. Le Cesne, T. le Chevalier, J. Bérille, 1994, European journal of cancer.

Prospective R andomized T rial o f D ocetaxel V ersus B est Supportive C are i n P atients W ith N on-Small-Cell L ung Cancer P reviously T reated W ith P latinum-Based Chemotherapy

J. Dancey, F. Shepherd, R. Ramlau, 2011 .

Phase II study of nitrosourea fotemustine as single-drug chemotherapy in poor-prognosis non-small-cell lung cancer.

J. Pujol, A. Monnier, J. Douillard, 1994, British Journal of Cancer.

Phase II study of fotemustine as second-line treatment after failure of immunotherapy in metastatic renal cell carcinoma

F. Chauvin, J. Bérille, T. Philip, 2004, Cancer Chemotherapy and Pharmacology.

Phase II study of docetaxel alternating with cisplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer

R. Stupp, U. Gatzemeier, M. Bargetzi, 2000, Anti-cancer drugs.

Randomized study of taxotere (TAX) versus best supportive care (BSC) in non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy

F. Shepherd, R. Ramlau, R. Gralla, 1999 .

Phase II study of docetaxel in the treatment of patients with advanced non-small cell lung cancer in routine daily practice.

R. Stupp, J. Pujol, J. Douillard, 2000, Lung cancer.

Phase II and pharmacokinetic study of fotemustine in inoperable colorectal cancer.

J. Bonneterre, P. Rougier, J. Bérille, 1993, European journal of cancer.

197 Interim results of a sequential administration of docetaxel (taxotere®) followed by Cisplatin-vindesine in chemotherapy naive patients with locally advanced or metastatic non small cell lung cancer (NSCLC)

D. Khayat, J. Bérille, J. Derenne, 1997 .

1084 Interim results of a phase II trial of docetaxel in combination with cisplatin in patients with metastatic or locally advanced non-small cell lung cancer (NSCLC)

J. Zalcberg, M. Millward, M. Friedlander, 1995 .

1096 Preliminary report of a phase II study of docetaxel (taxotere® and cisplatin in advanced non small cell lung cancer (NSCLC)

N. Ibrahim, A. Monnier, J. Douillard, 1995 .

Cetuximab plus radiochemotherapy in locally advanced anal cancer: Interim results of the French multicenter phase II trial ACCORD16.

J. Pignon, Y. Bécouarn, J. Bérille, 2011, Journal of Clinical Oncology.

A phase II study of docetaxel and vinorelbine combination chemotherapy in patients with advanced non-small cell lung cancer.

E. Lemarié, B. Milleron, A. Monnier, 2000, European journal of cancer.

A prospective randomized trial of Taxotere versus best supportive care (BSC) in patients with non-small cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy: Survival update

J. Dancey, F. Shepherd, R. Ramlau, 2000 .

Phase II multicentre study of the nitrosourea fotemustine in inoperable squamous cell lung carcinoma.

P. Berthaud, T. le Chevalier, J. Bérille, 1989, European journal of cancer & clinical oncology.

A phase III randomized, open-label multicenter trial to evaluate the benefit of leuprorelin acetate for 24 months after radical prostatectomy in patients with high risk of recurrence (AFU-GETUG 20/0310).

S. Culine, L. Salomon, J. Bérille, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of pirarubicin in advanced non-small cell lung cancer.

R. Arriagada, P. Hérait, T. Tursz, 1989, European Journal of Cancer and Clinical Oncology.

Proposal for size justification of expanded cohort at phase-2-recommended dose

C. Fournier, J. Bérille, N. Penel, 2011, Investigational New Drugs.

Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.

T. Conroy, M. Ychou, C. Bascoul-Mollevi, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I dose-escalation study of a novel antitumor agent, SR271425, administered intravenously in split doses (d1–d2–d3) in patients with refractory solid tumors

M. Campone, P. Fumoleau, J. Bérille, 2007, Cancer Chemotherapy and Pharmacology.